We were awarded the Ferenc Bojan Young Investigator Award at the @EPHconference. Happy that our work got recognised and the Bus Santé is continuing to produce relevant public health research. @iguessous @Hopitaux_unige @unige_en @UNIGEnews

RT @Larvol: Which companies are driving the future of #BreastCancer treatment? @Larvol CLIN highlights the innovators who stood out at @SAB…

RT @Larvol: Discover key discussions and reactions on top trials from @SABCSSanAntonio 2024 with @Larvol CLIN. Learn More:

RT @IlanaSchlam: Wrapping up another fantastic #SABCS! Amazing, practice-changing data were presented. I’ve updated the algorithms and…

RT @oncodaily: 📡SOLTI-2103 VALENTINE Trial: Phase II Trial of Neoadjuvant Patritumab Deruxtecan vs. Chemotherapy for High-Risk HR+/HER2- Ea…

CamRelief, early TNBC, NACT +/- periop Camrelizumab (#SABCS24): - Cape allowed. - pCR rate improved (12% delta). - No EFS benefit yet (immature). Looking similar to GeparDouze. Diff with KN522 a question of anti-PD-1 vs anti-PD-L1, or cape being permitted? Both? Asian patients?

GeparDouze trial in early TNBC, NACT +/- periop Atezo at #SABCS24: - No EFS benefit - Cape allowed from Feb 2020 (why not earlier?) - No clear EFS differences by pCR status. Another negative trial for Atezo. How would KN522 results have differed if Cape had been allowed? 🤔

Anthracyclines in High Genomic Risk N0 HR+/HER2- EBC in TAILORx (#SABCS24): - RS 31 cutoff predicts 5y DRFI benefit with Anthra -mainly in postmenopausal (OFS effect?). - Note: ttt not randomised. 🧠 Vogl NY asks: Could Ki67 offer similar predictive insights?🙃

ZEST trial: Niraparib in patients with MRD (ctDNA+ during ctDNA surveillance) EBC (TNBC or tBRCA+) (#SABCS24): - Only 147/1901 patients had ctDNA+, 40 randomised - 800 to be randomised - study terminated Cautionary tale on the challenges of doing MRD-guided RCTs in EBC.

PATINA trial in HER2+ ER+ MBC, Trast+Pert+ET +/- Palbociclib (#SABCS24): - PFS benefit: 44 vs 29 months👏 - No clear OS benefit - Worse toxicity profile. DB09 data in 6 months and T-DXd likely moving to 1L. the future role of PATINA uncertain. Complex decisions ahead!🤔

Important study from EBCCTG on obesity & prognosis in EBC (#SABCS24): - Strong link: Worse outcomes with higher BMI. - Especially impactful in premenopausal women. - Independent of LN and ER status. A stark reminder of the broader consequences of the obesity epidemic. 🌍

COMET trial, active monitoring vs surgery (+/-RT) in low risk DCIS at #SABCS24 : - 2y IBC rate non-inferior (dif: 1.7%) - most got Adj ET - 31% women didn't adhere to randomisation, favouring AM But is QoL better than surgery + RT w/o ET?

Key insights for "Good Risk" DCIS patients with BCS and forgoing Adj RT at #SABCS24 : - Adjuvant tamoxifen shows invasive IBR benefit. - No difference in contralateral breast events noted. Crucial data for informed discussions on de-escalating RT vs ET in DCIS management. 🤝

EUROPA trial 1st interim analysis at #SABCS24 : ET only vs RT only for women >70 with Luminal A pT1pN0 tumors. QoL significantly better without ET as expected Awaiting IBTR data. Identifying who can forgo ET remains a priority. More trials will join EUROPA. Stay tuned! :)

RT @oncodaily: 📌Highlights from Day 1 of SABCS 2024 SABCS 2024, taking place from December 10-13 in San Antonio, TX, is featuring expert-…

@EpiEllie there's also a lack of understanding of what a PhD is...a struggle to survive, do what hasn't been done, most often fail, try to see the good points, learn from the experience and acquire the resilience for a career in academia/industry... Good luck getting that from ChatGPT

EMBER-3 in @NEJM ahead of #SABCS24 presentation : ✨ IML mono: marginal PFS edge vs Fulv; OS trends favor IML. 📊 ESR1m? IML likely better. 💡 Key insight: IML+Abema effective post-CDK4/6i (🟢Palbo 60%, 🔵Ribo 30%). New 2L standard? 🤔For whom?

@DrHBurstein maybe could be interesting to find those that benefit most from pembro and for whom we could maybe de-escalate chemo intensity (e.g. anthracyclines)

Biomarker analysis of KN522 Interesting potential predictors of increased Pembro benefit (e.g. TMB). IMO, if confirmed, maybe could pave the way to chemotherapy intensity de-escalation in this population (~8% of total). Also interesting to study how this relates to TILs. #SABCS24

SOLTI Valentine: HER3-DXd +/- ET or Chemo in HR+/HER2- high risk EBC. pCR rates similar. Yet, it's a randomised noncomparative trial...is it legit to compare? HER3-DXd is effective. IMO, we'll need better EFS (or better QoL) for routine use (after a bigger trial).#SABCS24

PADMA study (ET+Palbo vs Chemo as 1L in MBC w/ indication for 1L chemo). Increased TTF & PFS w/ 1L ET+Palbo. Similar OS. Similar results to Right Choice w/ Ribo. Soon results from AMBER w/ Abema. Yet, evidence seems to support ET+CDK4/6i as 1L in most cases.#SABCS24